Gelteq Limited stock jumps in premarket after CBD gel study; what’s next for GELS
NEW YORK, Jan 14, 2026, 08:42 AM EST — Premarket Gelteq Limited shares surged roughly 48% to $1.23 in premarket action Wednesday, following a 6.4% gain at Tuesday’s close. (StockAnalysis) The Nasdaq-listed biotech revealed that a recent preclinical study demonstrated its ingestible gel delivery platform boosts cannabidiol (CBD) absorption over an FDA-approved oil-based option. Gelteq also indicated these findings might accelerate plans for a medicinal cannabis launch in Australia. (Gelteq Limited) This is significant as the company relies on Australia’s Special Access Scheme, which lets health practitioners obtain “unapproved” therapeutic goods for individual patients via specific channels. According to the